Nomura Adjusts BeiGene Price Target to $347.02 From $316.65, Maintains Buy Rating

Published on 03/03/2025 at 23:12 - Modified on 03/03/2025 at 23:23

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about BeOne Medicines Ltd.

Nomura Adjusts BeOne Medicines Price Target to $352.60 From $347.02, Maintains Buy Rating	18/07	MT
Nomura Adjusts BeOne Medicines' Price Target to HK$209.92 From HK$206.60, Keeps at Buy	18/07	MT
RBC Raises Price Target on BeOne Medicines to $349 From $311, Keeps Outperform Rating	16/07	MT
EU Commission OKs BeOne's Tevimbra Combo for Rare Head & Neck Cancer	10/07	MT
BeOne Medicines Gets European Commission Approval for Nasopharyngeal Carcinoma Combination Treatment	10/07	MT
European Commission Approves TEVIMBRA®? in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma	10/07	CI
Biocytogen Pharmaceuticals Co., Ltd. Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development	10/07	CI
BeiGene, Ltd. - Special Call	27/06
Beone Medicines Ltd. Showcases Oncology Pipeline At R&D Day	26/06	CI
Beone Medicines Insider Sold Shares Worth $830,360, According to a Recent SEC Filing	26/06	MT
BeOne Medicines Ltd. Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA	25/06	CI
BeOne Medicines' Brukinsa Tablets Recommended by European Medicine Committee	25/06	MT
Sector Update: Health Care Stocks Lean Lower Premarket Thursday	12/06	MT
BeOne Medicines Ltd Showcases Breakthrough Data in CLL and MCL at EHA 2025	12/06	CI
BeOne Medicines Says Data Shows High Overall Response of Sonrotoclax plus BRUKINSA in CLL, MCL Patients	12/06	MT
BeOne Medicines Gets FDA Approval for Brukinsa Tablet in Blood Cancer Indications	12/06	MT
Glenmark Pharmaceuticals to Launch New Blood Cancer Treatment in India	10/06	MT
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025	02/06	CI
BeOne Medicines Ltd. Presents New Sequoia Study Results Reinforcing Brukinsa's Differentiated Profile with or Without Venetoclax in Frontline Cll At Asco 2025	31/05	CI
Health Rounds: Amgen blood platelet booster helps patients who need chemotherapy	30/05	RE
Beone Medicines Launches Following Redomiciliation to Switzerland, Marking New Chapter in Global Oncology	28/05	CI
BeiGene Changes Name to BeOne Medicines, Completes Redomiciliation to Switzerland	27/05	MT
Sector Update: Health Care Stocks Rise Premarket Tuesday	27/05	MT
Sector Update: Health Care	27/05	MT
BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use	27/05	DJ